Chimeric antigen receptor (CAR) T-cell immunotherapy is rapidly emerging as a promising
novel treatment for malignancies. To broaden the success of CAR T-cell treatment for …

Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is
already widely adopted in clinical practice. On the other hand, the development of CAR-T …

Background Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent and
durable effects in B-cell malignancies. However, antigen loss or downregulation is a …

Background: Immunotherapy utilizing T cells genetically modified to express chimeric
antigen receptors (CARs) is rapidly emerging as a promising novel treatment for …

Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …

Background Autologous T cells engineered to express a chimeric antigen receptor (CAR)
specific for CD19 molecule have transformed the therapeutic landscape in patients with …

CD19 chimeric antigen receptor (CAR) T cells have shown robust efficacy in relapsed and
refractory acute lymphoblastic leukemia (R/R ALL), but compromising result in chronic …

Simple Summary Chimeric antigen receptor (CAR) T cell therapy represents a major
advancement in cancer treatment. Recently, FDA approved CAR-T cells directed against the …

Chimeric antigen receptor T-cell immunotherapy (CAR-T) has shown remarkable efficacy in
treating tumors of lymphopoietic origin. Herein, we demonstrate an effective CAR-T cell …

Backgrounds Chimeric antigen receptor (CAR)-T cell therapy has achieved unprecedented
success in treating hematopoietic malignancies. However, this cell therapy is hampered in …